The CRF System as a Therapeutic Target for Neuropsychiatric Disorders

Jeff Sanders, Charles Nemeroff

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The major neuropsychiatric disorders are devastating illnesses that are only modestly responsive to treatment. Improving the treatment of these conditions will require innovative new strategies that depart from previously focused-on pharmacological mechanisms. Considerable preclinical and clinical data indicate corticotropin-releasing factor (CRF) signaling as a target for new psychotropic drug development. Here we review alterations in the CRF system reported in several psychiatric conditions. We also examine the preclinical work that has dissected the distinctive roles of CRF receptors in specific circuits relevant to these disorders. We further describe the clinical trials of CRF1 receptor antagonists that have been conducted. Although these clinical trials have thus far met with limited therapeutic success, the unfolding complexity of the CRF system promises many future directions for studying its role in the etiology and treatment of neuropsychiatric conditions.

Original languageEnglish (US)
Pages (from-to)1045-1054
Number of pages10
JournalTrends in Pharmacological Sciences
Volume37
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Corticotropin-Releasing Hormone
Clinical Trials
Corticotropin-Releasing Hormone Receptors
Psychotropic Drugs
Psychiatry
Therapeutics
Pharmacology
Networks (circuits)

Keywords

  • CRF
  • polymorphisms
  • preclinical
  • psychopathology
  • stress
  • treatment

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

The CRF System as a Therapeutic Target for Neuropsychiatric Disorders. / Sanders, Jeff; Nemeroff, Charles.

In: Trends in Pharmacological Sciences, Vol. 37, No. 12, 01.12.2016, p. 1045-1054.

Research output: Contribution to journalReview article

@article{a85bcf67b92c4b1aa3065cef69d02ee2,
title = "The CRF System as a Therapeutic Target for Neuropsychiatric Disorders",
abstract = "The major neuropsychiatric disorders are devastating illnesses that are only modestly responsive to treatment. Improving the treatment of these conditions will require innovative new strategies that depart from previously focused-on pharmacological mechanisms. Considerable preclinical and clinical data indicate corticotropin-releasing factor (CRF) signaling as a target for new psychotropic drug development. Here we review alterations in the CRF system reported in several psychiatric conditions. We also examine the preclinical work that has dissected the distinctive roles of CRF receptors in specific circuits relevant to these disorders. We further describe the clinical trials of CRF1 receptor antagonists that have been conducted. Although these clinical trials have thus far met with limited therapeutic success, the unfolding complexity of the CRF system promises many future directions for studying its role in the etiology and treatment of neuropsychiatric conditions.",
keywords = "CRF, polymorphisms, preclinical, psychopathology, stress, treatment",
author = "Jeff Sanders and Charles Nemeroff",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.tips.2016.09.004",
language = "English (US)",
volume = "37",
pages = "1045--1054",
journal = "Trends in Pharmacological Sciences",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - The CRF System as a Therapeutic Target for Neuropsychiatric Disorders

AU - Sanders, Jeff

AU - Nemeroff, Charles

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The major neuropsychiatric disorders are devastating illnesses that are only modestly responsive to treatment. Improving the treatment of these conditions will require innovative new strategies that depart from previously focused-on pharmacological mechanisms. Considerable preclinical and clinical data indicate corticotropin-releasing factor (CRF) signaling as a target for new psychotropic drug development. Here we review alterations in the CRF system reported in several psychiatric conditions. We also examine the preclinical work that has dissected the distinctive roles of CRF receptors in specific circuits relevant to these disorders. We further describe the clinical trials of CRF1 receptor antagonists that have been conducted. Although these clinical trials have thus far met with limited therapeutic success, the unfolding complexity of the CRF system promises many future directions for studying its role in the etiology and treatment of neuropsychiatric conditions.

AB - The major neuropsychiatric disorders are devastating illnesses that are only modestly responsive to treatment. Improving the treatment of these conditions will require innovative new strategies that depart from previously focused-on pharmacological mechanisms. Considerable preclinical and clinical data indicate corticotropin-releasing factor (CRF) signaling as a target for new psychotropic drug development. Here we review alterations in the CRF system reported in several psychiatric conditions. We also examine the preclinical work that has dissected the distinctive roles of CRF receptors in specific circuits relevant to these disorders. We further describe the clinical trials of CRF1 receptor antagonists that have been conducted. Although these clinical trials have thus far met with limited therapeutic success, the unfolding complexity of the CRF system promises many future directions for studying its role in the etiology and treatment of neuropsychiatric conditions.

KW - CRF

KW - polymorphisms

KW - preclinical

KW - psychopathology

KW - stress

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=84995799449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995799449&partnerID=8YFLogxK

U2 - 10.1016/j.tips.2016.09.004

DO - 10.1016/j.tips.2016.09.004

M3 - Review article

C2 - 27717506

AN - SCOPUS:84995799449

VL - 37

SP - 1045

EP - 1054

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 12

ER -